Cargando…

ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells

Triple-negative breast cancer (TNBC) is a type of breast cancer that is characterized by the lack of expression of estrogen and progesterone receptors, and epidermal growth factor receptor 2. Therefore, there is an absence of a specific target for effective therapy in TNBC. Cisplatin is usually empl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yang, Wang, Lu, Gao, Peng, Sun, Zhiguo, Li, Ning, Lu, Yanqin, Shen, Jianglun, Sun, Jian, Yang, Yiming, Dai, Hao, Cai, Haifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192754/ https://www.ncbi.nlm.nih.gov/pubmed/30226569 http://dx.doi.org/10.3892/ijmm.2018.3842

Ejemplares similares

Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2014)

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2022)

AKT isoforms have discrete expression in triple negative breast cancers and roles in cisplatin sensitivity
por: Wadhwa, Bhumika, et al.
Publicado: (2020)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
por: Gajan, Ambikai, et al.
Publicado: (2021)

Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity
por: Heijink, Anne Margriet, et al.
Publicado: (2019)

Urtica dioica Leaf Infusion Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Cisplatin Treatment
por: Nafeh, Guy, et al.
Publicado: (2023)

Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT
por: Jin, Yujin, et al.
Publicado: (2019)

ZNF213 negatively controls triple negative breast cancer progression via Hippo/YAP signaling
por: Liu, Yun, et al.
Publicado: (2021)

circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression
por: Chen, Bo, et al.
Publicado: (2018)

The Blood of the Isles
por: McKee, Shane
Publicado: (2007)

Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models
por: Balza, Enrica, et al.
Publicado: (2021)

Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells
por: Li, Shujun, et al.
Publicado: (2020)

ISL-1 promotes pancreatic islet cell proliferation by forming an ISL-1/Set7/9/PDX-1 complex
por: Yang, Zhe, et al.
Publicado: (2015)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance
por: Hill, David P., et al.
Publicado: (2019)

pH sensitive peptide functionalized nanoparticles for co-delivery of erlotinib and DAPT to restrict the progress of triple negative breast cancer
por: Wan, Xu, et al.
Publicado: (2019)

Triple negative breast cancer: Pitfalls and progress
por: Zagami, Paola, et al.
Publicado: (2022)

Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
por: Lee, Jin Sun, et al.
Publicado: (2020)

Research progress on immunotherapy in triple-negative breast cancer (Review)
por: Zhang, Xiaoxiao, et al.
Publicado: (2022)

ISL1 is upregulated in breast cancer and promotes cell proliferation, invasion, and angiogenesis
por: Li, Lin, et al.
Publicado: (2018)

L'isle Joyeuse
por: Debussy, Claude 1862-1918
Publicado: (1986)

Giants of the British Isles
por: Bradley, Lisa, et al.
Publicado: (2011)

Medicine in the British Isles
por: McCrae, Thomas
Publicado: (1930)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
por: Lee, Jung Ok, et al.
Publicado: (2019)

Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer
por: Park, In Hae, et al.
Publicado: (2018)

MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer
por: Liu, Xiaoping, et al.
Publicado: (2015)

Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer
por: Xu, Junnan, et al.
Publicado: (2018)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

A review of current progress in triple-negative breast cancer therapy
por: Shen, Meiying, et al.
Publicado: (2020)

miR-638 mediated regulation of BRCA1affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer
por: Tan, Xiaohui, et al.
Publicado: (2014)

Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
por: Wang, Junbin, et al.
Publicado: (2017)

Aspirin inhibits tumor progression and enhances cisplatin sensitivity in epithelial ovarian cancer
por: Guo, Jianfeng, et al.
Publicado: (2021)

Cisplatin Loaded Multiwalled Carbon Nanotubes Induce Resistance in Triple Negative Breast Cancer Cells
por: Badea, Madalina Andreea, et al.
Publicado: (2018)

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
por: Kalra, Maitri, et al.
Publicado: (2021)

Growth Inhibition of Triple-Negative Breast Cancer: The Role of Spatiotemporal Delivery of Neoadjuvant Doxorubicin and Cisplatin
por: Salerno, Dominick, et al.
Publicado: (2021)

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
por: Telli, Melinda L., et al.
Publicado: (2022)

Synergistic effects of combined cisplatin and Clinacanthus nutans extract on triple negative breast cancer cells
por: Abu Bakar, Nur Fitriyani Afiqah Binti, et al.
Publicado: (2023)

Asymmetric, amphiphilic RGD conjugated phthalocyanine for targeted photodynamic therapy of triple negative breast cancer
por: Li, Rui, et al.
Publicado: (2022)

Genomic Index of Sensitivity to Chemotherapy for Triple Negative Breast Cancer
por: C, Ahammad Sameer, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hal17hjlv5b5tuq1lvrl3edfg6